hFcRn(SD)

Fig1. Expression characterization of hFCRN in hFCRN knockin rat by Western blot. 

Abbr. HO, homozygous; WT, wild type.

Fig.2 Detection of Rat IgG1(A) expression in serum of WT SD rat and HO hFCRN(SD) rat by ELISA.  Serum were collected from wild-type SD rat (n=6, female, 6-8 weeks old) and HO hFCRN(SD) rat (n=6, female, 6-8 weeks old), and analyzed by ELISA with anti-Rat IgG1 ELISA kit. 

Abbr.  HO, homozygous; WT, wild type.

Fig.3  Blood concentration curve of test articles in hFcRn/hALB dKI rats (NR-HU-233317), which were generated by crossing hFCRN(SD)(NR-HU-200002) with hALB(SD)(NR-HU-200001). 

In hFcRn/hALB dKI rats, the half-life time: TA-N434A > TA-YTE > TA. (In cooperation with the third party)

Fig.4 PK study of Keytruda (A)  and Cyramza(B) in  hALB/hFCRN dKl rat (NR-HU-233317), which were generated by crossing hFCRN(SD)(NR-HU-200002) with hALB(SD)(NR-HU-200001). (n=3/time point/group) 

Fig.5 Pharmacokinetic analysis of IBI112 in hFCRN(SD) rat. (A) Body weight. (B) Pharmacokinetic analysis parameters. On Day 0, Sprague-Dawley (SD) rats and hFcRn(SD) transgenic rats were intravenously injected via the tail vein with IBI112 (hIgG1 Fc) and the YTE-modified IBI112 antibody (5 mg/kg), respectively. Blood was drawn at the indicated times, and serum was obtained for pharmacokinetic analysis (n=3 females, 6-8 weeks old). The results revealed a significantly prolonged half-life of the YTE-modified IBI112 antibody in hFcRn(SD) rats compared to wild-type (WT) SD rats. Data are shown as mean ± SEM.